017 – Ana Maiques
Ana Maiques is the CEO of Neuroelectrics. She completed her Bachelors in Economics at the Universitat de Barcelona and an MBA at London Metropolitan University.
Top 3 Takeaways
- Neurotechnology companies can sell research tools as a way to gain expertise and develop their technology.
- Neuroelectrics’ big advantage is the ability of their software to personalize stimulation parameters for their desired indications for use.
- Ana will only sell her devices to groups using them for medical purposes.
- [0:54] Ana’s background.
- [1:30] Using math and physics to decode brain signals.
- [2:10] What Neuroelectrics is all about.
- [3:10] The products Neuroelectrics currently has on the market.
- [3:45] The disease indications for Neuroelectrics’ device.
- [5:20] Who should you focus on, managed patients or refractory patients?
- [7:18] Invasive vs. non-invasive neurostimulation and recording.
- [8:35] Balancing research tools and medical devices.
- [10:40] The software is what differentiates Neuroelectrics.
- [12:10] Synthesizing product feedback.
- [13:30] Other markets for Neuroelectrics.
- [14:30] Neuroethics of cognitive enhancement.
- [17:00] Ana’s favorite neuroscience books.
Disclaimer: We actively write about the themes in which we invest: artificial intelligence, robotics, virtual reality, and augmented reality. From time to time, we will write about companies that are in our portfolio. Content on this site including opinions on specific themes in technology, market estimates, and estimates and commentary regarding publicly traded or private companies is not intended for use in making investment decisions. We hold no obligation to update any of our projections. We express no warranties about any estimates or opinions we make.